羟基氯喹
医学
痹症科
系统性红斑狼疮
皮肤病科
红斑狼疮
内科学
免疫学
2019年冠状病毒病(COVID-19)
疾病
抗体
传染病(医学专业)
作者
Tatsuya Shimomatsu,Nobuo Kanazawa,Naoya Mikita,Yumi Nakatani,Hongjin Li,Yutaka Inaba,Takaharu Ikeda,Toshikazu Kondo,Fukumi Furukawa
标识
DOI:10.3109/14397595.2016.1140711
摘要
To evaluate the effect and safety of hydroxychloroquine (HCQ) on lupus erythematosus (LE)-like skin lesions in the MRL/lpr mouse, a model for systemic LE (SLE).We divided the MRL/lpr mice into three groups that were given: (1) drinking water, (2) HCQ at a dose of 4 mg/kg/d, or (3) HCQ at a dose of 40 mg/kg/d. The HCQ was administered to examine the effect and safety of HCQ on skin lesions and the number of infiltrating cells including mast cells in the dermis.Six of 13 mice in the group given drinking water, 3 of 11 mice in the group administered low-dose HCQ (4 mg/kg/d), and 1 of 10 mice in the group administered high-dose HCQ (40 mg/kg/d) presented the skin lesions. The average number of mast cells was 81, 50, and 12 (magnification, ×100), the mortality rate was 24%, 8%, and 9% and the mean body weight gain was 4.6 g, 8.0 g and 5.1 g, respectively.HCQ was demonstrated to decrease the appearance of LE-like lesions and the number of mast cells in the dermis. Furthermore, there were no obvious systemic adverse effects. This study provides evidence that suggests benefits in human patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI